Page 24 - Pharma Sector

Zensar acquires BridgeView to expand into biopharma, life sciences industry

The acquisition is expected to be completed tentatively within 2-3 weeks

Pharma and healthcare sector seals $4.1 bn deals in Q2 2024: Report

The average deal size also saw a jump, rising from $9.7 million in Q1 calendar year 2024 to $74 million in Q2 2024

Lupin divests women's health specialty biz in US to Evofem Biosciences

Company says divestment aligns US specialty business with therapeutic areas like respiratory, neurology

Mankind Pharma rallies 5% after 3.7 mn shares change hands via block deal

Mankind Pharma, the domestic pharmaceutical major's stock price surged up to 5.27 per cent at Rs 2,215 per share on the BSE in Wednesday's intraday trade

Centre fails to form policy on online sale of drugs ahead of HC deadline

The Delhi HC had in March this year, given the government a final opportunity to frame a policy within four months, failing which, the court had stated it would hear the matter on merits

Indian pharmaceutical market registers over 8% growth in June 2024

GSK's antibiotic drug Augmentin and USV's anti-diabetic drug Glycomet GP continued to be the top-selling medicine brands with sales of Rs 76 crore and Rs 66 crore, respectively

Indian pharma firms seek govt tax reliefs, incentives to spur innovation

The upcoming budget would be Modi's first major policy announcement in his third term as prime minister

This pharma stock has surged 16% on Friday; zoomed over 100% so far in CY24

Shilpa Medicare hit a multi-year high of Rs 672.50, rallied 16% after the company's CDMO customer reported positive results from pivotal clinical trial & placed binding purchase order.

Healthcare at new high; Lupin, Glenmark among 5 stocks for up to 15% upside

5 breakout pharma stocks: Glenmark, Lupin, Laurus Labs, Dr Lal PathLabs and Zydus Life can potentially rally up to 15 per cent, suggest charts.

Mumbai-based Wockhardt to launch its novel antibiotic Zaynich by FY25-end

Global launch in FY26 after multinational clinical trial ends

Orchid Pharma join hands with Cipla to launch new antibiotic in India

The partnership between Orchid Pharma and Cipla combines Orchid's innovative drug development capabilities with Cipla's extensive distribution network and market presence

India to make Ozempic-like drugs for diabetes, obesity under PLI by 2026

GLP-1RA works by activating GLP-1 receptors in the pancreas, which leads to enhanced insulin release and reduced glucagon release responses

Online pharmacy players look for regulatory framework for industry

A division bench of the Madras HC has set aside an earlier order that disallowed them to engage in digital sale of medicines

'$10 bn opportunity up for grabs in off patent drug market by 2029'

As many as 15 blockbuster drugs whose revenues worth USD 112 billion will be off-patented during 2023 to 2029 and the Indian pharma industry will have a growth opportunity of USD 10 billion in the form of generics (including complex), a top official of Pharmaceuticals Export Promotion Council of India (Pharmexcil), a body under the Department of Commerce said on Thursday. Addressing a press conference, Udaya Bhaskar, Director General of Pharmexcil also said Indian pharma exports recorded 8.85 per cent growth during April and May this year at USD 4.73 billion against USD 4.35 billion during the same period last fiscal. He further said with the advent of quality concerns raised by global regulatory agencies, Pharmexcil's priority has been shifted to quality management and imbibing quality culture in the industry by way of organising capacity building programmes in states to uphold the image of Indian pharma on global platform. According to the pharma exports body, India has 748 US Foo

CDSCO cracks whip on drug manufacturing units over quality lapses

Shuts down 36% of facilities for failing to meet quality standards

Pharma industry body mulling policy framework to guide cos on cybercrime

The Indian pharma companies are better off in terms of facing cyber-attacks now as compared to a few years ago

Indian pharma sites outpace global standards in USFDA inspections for 2023

The USFDA categorised 13 per cent (19 out of 145 inspections) of Indian facilities as 'Official Action Indication'(OAI), which is lower than the global average of 15 per cent OAIs

Alkem Labs shares surge 5% on USFDA's VAI status for Baddi facility

Shares of Alkem Labs gain up to 4.77 per cent at Rs 5,250.30 per share on the BSE in Tuesday's intraday trade

Govt may overhaul PLI schemes: Quarterly incentive payments on the table

In a bid to cut the delay in processing incentive claims, the government is looking at switching to a quarterly disbursement of incentives

Biocon searches for partner to test generic Wegovy, Ozempic in China

Biocon's generics would join at least 15 other generics or biosimilars in development by Chinese drugmakers ahead of an expiry of patent protection on semaglutide